
Degron Therapeutics
- AI assistants read this profile 31 times in 14 days
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
About
Degron Therapeutics develops novel molecular glue degrader (MGD) drugs using its proprietary GlueXplorer® platform to target historically intractable disease targets. This platform leverages a large, structurally differentiated compound library and advanced screening systems to address the challenges of rational MGD design. The company aims to "drug the undruggable" by creating new therapeutic options for diseases.
Show 6 more similar companies
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, HealthTech
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Healthcare
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
Shares Biotechnology, Pharmaceuticals
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Pharmaceuticals
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to Degron Therapeutics?
People comparing tools land here. Get listed beside these.
Copy Degron Therapeutics's SEO strategy
How often they publish, which searches their posts chase and their newest posts. Then outrank them.
All funding rounds
Key facts
- Website
- degrontx.com
- Headquarters
- San Diego, California, USA
- Founded
- 2020
- Founder
- Stuart L. Schreiber
- Employees
- 24
- Total funding
- $40M (Series A Extension)
- Business model
- B2B
Funding rounds
- $40M14 May 2026
Led by LAPAM CAPITAL
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 14 May 2026 | Series A Extension | $40M | LAPAM CAPITAL |
Benchmarking
See how your site ranks against 16,849 startups
Degron Therapeutics sits in the 32nd percentile for Domain Rating. Check where yours lands, free.
Degron Therapeutics has a Domain Rating of 25, the 32nd percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Below median
Check yoursAgent Readiness
Bottom 25%
Scan yoursSite Speed
Below median
PageSpeedData Trust
Below median
Security
Click to scan
Agent Readiness
Can AI agents use your site?
Degron Therapeutics scores 27. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentGet notified when Degron Therapeutics changes
Used Degron Therapeutics? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Is Degron Therapeutics growing?
Yes, fast. Our data shows it raised $40M in a Series A Extension in May 2026.
Who owns Degron Therapeutics?
Degron Therapeutics is privately held, owned by its founders and investors. Investors on record include LAPAM CAPITAL, GTJA Investment Group, Fortune Capital and CSPC & Growth. Exact stakes are not public.
Are there companies like Degron Therapeutics?
Yes. We list 6 companies like Degron Therapeutics, including Moderna, Epicrispr Biotechnologies and Pixelgen Technologies.
Is Degron Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Degron Therapeutics is 57 out of 100, a use-caution rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Degron Therapeutics raised?
Degron Therapeutics has raised a total of $40M in funding. The most recent round on record is Series A Extension.
How many employees does Degron Therapeutics have?
Degron Therapeutics has approximately 24 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for Degron Therapeutics:
Company details: from public sources. Funding: 1 round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch Degron Therapeutics and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini

